This is an aggregated industry headline. Read the full story at PharmaVoice →
BMS under pressure in schizophrenia; Summit/Akeso on a winning streak
While the large pharma's new drug Cobenfy has stumbled in schizophrenia, it could find new life in Alzheimer's disease
By PharmaVoice
· Jun 5, 2026
· via PharmaVoice
Image: PharmaVoice
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Widespread misconceptions about Type 1 diabetes could be contributing to a reluctance to get screened for the …
The WeekFierceBiotech ↗
Bristol Myers Squibb has entered into an expanded collaboration with Nvidia to create the biggest supercompute…
The WeekBriefing
Medicare’s proposal to trim hospital reimbursement for specific drugs and imaging services could extend site-n…